MCI Conversion Prediction Using 3D Zernike Moments and the Improved Dynamic Particle Swarm Optimization Algorithm
| dc.contributor.author | Bolourchi, Pouya | |
| dc.contributor.author | Gholami, Mohammadreza | |
| dc.contributor.author | Moradi, Masoud | |
| dc.contributor.author | Beheshti, Iman | |
| dc.contributor.author | Demirel, Hasan | |
| dc.date.accessioned | 2026-02-06T18:24:00Z | |
| dc.date.issued | 2023 | |
| dc.department | Doğu Akdeniz Üniversitesi | |
| dc.description.abstract | Mild cognitive impairment (MCI) conversion prediction is a vital challenge in the area of Alzheimer's disease (AD) as it could determine possible treatment pathways for AD patients. In this work, we presented a robust MCI conversion prediction framework based on the 3D-Zernike Moment (3D-ZM) method that generates statistical features (e.g., shape, texture, and symmetry information) from 3D-MRI scans and improved dynamic particle swarm optimization (IDPSO) that finds an informative sub-set of Zernike features for MCI conversion prediction. We quantified the efficiency of the proposed prediction framework on a large sample of MCI patients including 105 progressive-MCI (pMCI) and 121 stable-MCI (sMCI) at the baseline from the ADNI dataset. Using the proposed MCI conversion prediction framework, pMCI patients were distinguished from sMCI patients with an accuracy exceeding 75% (sensitivity, 83%, and specificity, 68%), which is well comparable with the state-of-the-art MCI conversion prediction approaches. Experimental results indicate that the 3D-ZM method can represent informative statistical patterns from 3D-MRI scans and IDPSO has a great capability to find meaningful statistical features for identifying MCI patients who are at risk of conversion to the AD stage. | |
| dc.description.sponsorship | Alzheimer's Disease Neuroimaging Initiative (ADNI), USA (National Institutes of Health) [U01 AG024904]; DOD ADNI, USA (Department of Defense) [W81XWH-12-2-0012]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research and Development, LLC.; Johnson and Johnson Pharmaceutical Research and Development LLC.; Lumosity; Lundbeck; Merck and Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; Transition Therapeutics; Canadian Institute of Health Research | |
| dc.description.sponsorship | Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI), USA (National Institutes of Health Grant U01 AG024904),and the DOD ADNI, USA (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research and Development, LLC.; Johnson and Johnson Pharmaceutical Research and Development LLC.; Lumosity; Lundbeck; Merck and Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institute of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. | |
| dc.identifier.doi | 10.3390/app13074489 | |
| dc.identifier.issn | 2076-3417 | |
| dc.identifier.issue | 7 | |
| dc.identifier.orcid | 0000-0003-3492-0617 | |
| dc.identifier.orcid | 0000-0003-4750-3433 | |
| dc.identifier.scopus | 2-s2.0-85152542691 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.uri | https://doi.org/10.3390/app13074489 | |
| dc.identifier.uri | https://hdl.handle.net/11129/9984 | |
| dc.identifier.volume | 13 | |
| dc.identifier.wos | WOS:000971213500001 | |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.language.iso | en | |
| dc.publisher | Mdpi | |
| dc.relation.ispartof | Applied Sciences-Basel | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WoS_20260204 | |
| dc.subject | Alzheimer's disease | |
| dc.subject | classification | |
| dc.subject | feature extraction | |
| dc.subject | improved dynamic PSO | |
| dc.subject | Zernike moment | |
| dc.title | MCI Conversion Prediction Using 3D Zernike Moments and the Improved Dynamic Particle Swarm Optimization Algorithm | |
| dc.type | Article |










